Clinuvel Pharmaceuticals Limited (ASX:CUV)
Clinuvel Pharmaceuticals Limited (ASX:CUV) is a global specialty pharmaceutical group focused on developing and commercialising treatments for patients with genetic, metabolic, systemic and life-threatening, acute disorders, as well as healthcare solutions for the general population.
As pioneers in photomedicine and the family of melanocortin peptides, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for systemic photoprotection, DNA repair, repigmentation and acute or life-threatening conditions who lack alternatives.
CLINUVEL's lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel and Australia as the world's first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP).
Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Singapore and the USA.